Tübingen (dpa) - The Tübingen bio-pharmaceutical company Curevac raised 517.5 million US dollars (around 431.5 million euros) from a capital increase.

After the option exercise, the number of common shares sold by the company rose to 5.75 million at an issue price of $ 90 each, as the company announced in Tübingen on Thursday.

CureVac has been listed on the Nasdaq New York Stock Exchange since August 2020.

Curevac is currently developing a coronna vaccine.

Like the vaccines from Biontech and Moderna, it is based on so-called “messenger RNA” (messenger RNA).

Through the cooperation with Bayer, Curevac hopes to be able to use its corona vaccine this summer.

In addition to Bayer, there are other cooperation partners such as Wacker Chemie from Munich and Rentschler Biopharma from Laupheim (Biberach district).

© dpa-infocom, dpa: 210204-99-301882 / 2


Announcement of the capital increase on January 28, 2021